1407814-95-2

Basic information

• Product Name: 5-bromo-7-(2-fluorobenzyl)imidazo[1,5-b]pyridazine
• Synonyms: 5-bromo-7-(2-fluorobenzyl)imidazo[1,5-b]pyridazine
• CAS NO: 1407814-95-2
• Molecular Weight: 306.137
• Mol File: 1407814-95-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 5-bromo-7-(2-fluorobenzyl)imidazo[1,5-b]pyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-7-(2-fluorobenzyl)imidazo[1,5-b]pyridazine(1407814-95-2)
• EPA Substance Registry System: 5-bromo-7-(2-fluorobenzyl)imidazo[1,5-b]pyridazine(1407814-95-2)

Safety Data

• Hazardous Substances Data: 1407814-95-2(Hazardous Substances Data)

Upstream product

• 451-81-0 2-(2-fluorophenyl)acetyl chloride 
• 1407814-92-9 7-(2-fluorobenzyl)imidazo[1,5-b]pyridazine 
• 1407814-85-0 2-(2-fluorophenyl)-N-[(6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)methyl]acetamide 
• 79416-27-6 methyl aminolevulinate 
• 920285-96-7 C₅H₉N₃O 

Downstream Products

• 1407815-02-4 7-(2-fluorobenzyl)imidazo[1,5-b]pyridazine-5-carboximidamide acetate 

Relevant articles and documents

Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure

The first-in-class soluble guanylate cyclase (sGC) stimulator riociguat was recently introduced as a novel treatment option for pulmonary hypertension. Despite its outstanding pharmacological profile, application of riociguat in other cardiovascular indications is limited by its short half-life, necessitating a three times daily dosing regimen. In our efforts to further optimize the compound class, we have uncovered interesting structure-Activity relationships and were able to decrease oxidative metabolism significantly. These studies resulting in the discovery of once daily sGC stimulator vericiguat (compound 24, BAY 1021189), currently in phase 3 trials for chronic heart failure, are now reported.

SUBSTITUTED IMIDAZOPYRIDINES AND THE USE THEREOF

The present application relates to novel substituted imidazopyridazines, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases and to their use for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.